Travere Therapeutics, Inc. Common Stock (TVTX) Financials
Key financial figures for Travere Therapeutics, Inc. Common Stock (Q2 2026).
- Revenue
- $170M
- Net Income
- -$35M
- EPS
- $-0.37
- Total Assets
- $799M
- Operating Cash Flow
- $58M
Full income statement, balance sheet, and cash flow for Travere Therapeutics, Inc. Common Stock on SentiSense.